Skip to main content

VRPX

Stock
Health Care
Biotechnology

Performance overview

VRPX Price
Price Chart

Forward-looking statistics

Beta
0.54
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.

Company info

SectorHealth Care
IndustryBiotechnology
Employees7
Market cap$1.6M

Fundamentals

Enterprise value-$1.2M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$71.00
Dividend per share
Revenue per share
Avg trading volume (30 day)$147
Avg trading volume (10 day)$181
Put-call ratio

Macro factor sensitivity

Growth
Credit
Liquidity
Inflation
Commodities
Interest Rates

Valuation

Dividend yield0.00%
PEG Ratio-0.36
Price to sales
P/E Ratio-0.36
Enterprise Value to Revenue
Price to book

Upcoming events

Next earnings dayNovember 16, 2023
Next dividend day
Ex. dividend day

News

Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate

On Friday, Virpax Pharmaceuticals, Inc.  VRPX completed the full study following the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and Development Agreement (CRADA).

Benzinga (February 14, 2025)
Virpax soars 292% after receiving initial FDA guidance on its treatment for SARS and flu

Virpax stock reached its highest price since going public earlier this year after the FDA issued guidance on a potential anti-viral product

Business Insider (August 17, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free